Firmonertinib + SHP2 inhibitor
2L+ NSCLC with EGFR Classical Mutations
Phase 1Phase 1 combination study
Key Facts
Indication
2L+ NSCLC with EGFR Classical Mutations
Phase
Phase 1
Status
Phase 1 combination study
Company
About ArriVent Biopharma
Founded in 2021, ArriVent Biopharma identifies and in-licenses promising drug candidates from global innovation hubs, particularly China, to develop them for worldwide markets. The company's mission is to ensure differentiated medicines for difficult-to-treat cancers reach global patient populations. Led by a team with a proven track record in drug development and approvals, ArriVent's strategy leverages deep oncology expertise and regulatory experience to maximize the potential of its pipeline.
View full company profile